Hua Medicine (Shanghai) Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 17 shareholders own 42.05% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.8%	Arch Venture Partners, L.P.	125,088,960	HK$198.9m	0%	1.98%
10.6%	VR Adviser, LLC	103,475,595	HK$164.5m	0%	1.22%
7.56%	WuXi PharmaTech Healthcare Fund I General Partner L.P.	74,029,635	HK$117.7m	0%	33.06%
3.97%	Li Chen	38,838,690	HK$61.8m	0%	no data
2.55%	Baillie Gifford & Co.	25,001,500	HK$39.8m	0%	no data
1.46%	E Fund Management Co., Ltd.	14,262,000	HK$22.7m	0%	no data
1.02%	Allspring Global Investments, LLC	10,017,126	HK$15.9m	6.8%	no data
0.87%	Chien Cheng Lin	8,499,295	HK$13.5m	0%	no data
0.44%	China Universal Asset Management Company Ltd.	4,299,000	HK$6.8m	0%	no data
0.43%	Lansdowne Partners Limited	4,223,151	HK$6.7m	0%	0.02%
0.32%	Matthews International Capital Management, LLC	3,174,538	HK$5.0m	0%	0.01%
0.018%	State Street Global Advisors, Inc.	180,398	HK$286.8k	-0.55%	no data
0.018%	Fullgoal Fund Management Co. Ltd.	180,000	HK$286.2k	0%	no data
0.015%	Robert Taylor Nelsen	150,000	HK$238.6k	0%	no data
0.007%	VL Asset Management Limited	69,000	HK$109.7k	0%	0.09%
0.0024%	Yiu Wa Tsui	24,000	HK$38.1k	0%	no data
0.0001%	Norges Bank Investment Management	1,001	HK$1.6k	-100%	no data